Clinical Trial Update: Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP). [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update reports that inhaled molgramostim is being studied in pediatric participants with autoimmune pulmonary alveolar proteinosis and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Pulmonary Alveolar Proteinosis

Drugs mentioned

• Molgradex (molgramostim)

Snippet

Sponsor: Savara Inc. | Conditions: Autoimmune Pulmonary Alveolar Proteinosis | Phase 3 | Status: RECRUITING